Iperkalemia cronica nei pazienti cardio – renali: q & a per il cardionefrologo pratico

Abstract

Chronic hyperkalemia in cardiorenal patients: Q&A for the cardio-nephrologists.

Chronic hyperkalemia is a serious medical condition often present in patients with chronic kidney disease (CKD) and heart failure (HF). It leads to poor outcomes and needs careful management by cardio-nephrologists. CKD, HF, diabetes and use of renin–angiotensin–aldosterone system inhibitors (RAASi) drugs are known to induce hyperkalemia.

The current therapeutic options are not optimal as shown by the large number of CKD and HF patients suffering from hyperkalemia.

The following review focuses on the main risk factors that lead to the development of hyperkalemia and provides a guide for the correct diagnosis and new approaches to therapy.

Keywords

Hyperkalemia Chronic kidney disease Heart failure RAASi Potassium-binder

Get full access to this article

View all access options for this article.

References

Rastegar

Soleimani

Hypokalaemia and hyperkalaemia. Postgrad Med J 2001; 77:759–764.

Hollander-Rodriguez

Calvert

Jr.

Hyperkalemia. Am Fam Phys 2006; 73:283–90.

Weiner

Wingo

CS.

Hyperkalemia: a potential silent killer. J Am Soc Nephrol 1998; 9:1535–1543.

Jain

Kotla

Little

et al . Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012; 109:1510–1513.

Schwinger

Erdmann

Heart failure and electrolyte disturbances. Methods Find Exp Clin Pharmacol 1992; 14:315–325.

Dargie

HJ.

Interrelation of electrolytes and renin-angiotensin system in congestive heart failure. Am J Cardiol 1990; 65:28E–32E.

Takaichi

Takemoto

Ubara

et al . Analysis of factors causing hyperkalemia. Intern Med 2007; 46:823–829.

Palmer

BF.

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585–592.

Ahuja

Freeman

Jr Mahnken

et al . Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000; 20:268–272.

10.

Reardon

Macpherson

DS.

Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?

Arch Intern Med 1998; 158:26–32.

11.

Michel

Martin-Pérez

Ruigómez

et al . Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. Eur J Heart Fail 2015; 17:205–213.

12.

Vardeny

Claggett

Anand

et al . Randomized Aldactone Evaluation Study (RALES) Investigators. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014; 7:573–579.

13.

Luo

Brunelli

Jensen

et al . Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol 2016; 11:90–100.

14.

Palmer

BF.

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585–592.

15.

Cada

Ingram

Levien

Baker

DE.

Canagliflozin. Hosp Pharm 2013; 48:855–867.

16.

Arruda

Batlle

Sehy

Roseman

Baronowski

Kurtzman

NA.

Hyperkalemia and renal insufficiency: role of selective aldosterone deficiency and tubular unresponsiveness to aldosterone. Am J Nephrol 1981; 1:160–167.

17.

Oxlund

Henriksen

Tarnow

Schousboe

Gram

Jacobsen

IA.

Low dose spironolactone reduces blood pressure in patients with resistant hypertension andype 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013; 31:2094–2102.

18.

Van den Driessche

Eenkhoorn

Van Gaal

De Block

. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth J Med 2009; 67:376–387.

19.

Wolf

Ritz

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005 67:799–812.

20.

National Clinical Guideline Centre (UK). Chronic Kidney Disease (Partial Update): early identification and management of chronic kidney disease in adults in primary and secondary care. National Institute for Health and Care Excellence 2014 (UK), London.

21.

Kosiborod

Rasmussen

Lavin

et al . Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014; 312(21):2223-2233.

22.

Weir

Bakris

Pitt

New agents for hyperkalemia. N Engl J Med 2015; 372(16):1570-1571.

23.

Bakris

Pitt

Weir

et al . Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015; 314(2):151–161.

24.

Durfey

Lehnhof

Bergeson

et al . Severe hyperkalemia: can the electrocardiogram risk stratify for short-term adverse events? West J Emerg Med 2017; 18(5):963-971.

25.

Brenner

Cooper

de Zeeuw

et al .Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861–869.

26.

Lewis

Hunsicker

Bain

Rohde

RD.

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456–1462.

27.

Epstein

Reaven

Funk

et al . Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015; 21:S212-220.

28.

Goraya

Simoni

C-H

Wesson

DE.

A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol CJASN 2013; 8:371–381.

29.

Nguyen

Ondrik

Zhufyak

et al . Hyperkalemia and potential pitfalls of sodium polystyrene sulfonate. JAAPA Off J Am Acad Physician Assist 2015; 28:41–45.

30.

Montaperto

Gandhi

Gashlin

Symoniak

MR.

Patiromer: a clinical review. Curr Med Res Opin 2016; 32(1):155–164.

31.

Pitt

Anker

Bushinsky

Kitzman

Zannad

Huang

IZ.

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011; 32(7):820–828.

32.

Bushinsky

Williams

Pitt

et al . Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int 2015; 88(6):1427–1433.

33.

Pitt

Bakris

Bushinsky

et al . Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015; 17(10):1057–1065.

34.

Weir

Bushinsky

Benton

et al . Effect of patiromer on hyperkalemia recurrence in older chronic kidney disease patients taking RAAS inhibitors. Am J Med 2018; 131(5):555-564.e3.

35.

Lesko

Offman

Brew

et al . Evaluation of the potential for drug interactions with patiromer in healthy volunteers. J Cardiovasc Pharmacol Ther 2017; 22(5):434-446.

36.

Ash

Singh

Lavin

Stavros

Rasmussen

HS.

A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int 2015; 88(2):404–411.

37.

Kosiborod

Rasmussen

Lavin

et al . Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014; 312(21):2223–2233.